Spectrum Pharmaceuticals Up Almost 6% Today (SPPI)

Spectrum Pharmaceuticals, Inc. SPPI continues to see buying interest, gaining almost 6% on back of news that a Phase 2 study of its drug, belinostat, reached its target enrollment. Here is the press release from last week in its entirety.